Credit Suisse Group Analysts Give Celgene (CELG) a $125.00 Price Target
Credit Suisse Group set a $125.00 price objective on Celgene (NASDAQ:CELG) in a research note released on Monday morning. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
CELG has been the topic of several other research reports. Royal Bank of Canada decreased their price target on Celgene from $166.00 to $148.00 and set a top pick rating on the stock in a research note on Friday, October 27th. Leerink Swann reissued a buy rating and set a $156.00 price target on shares of Celgene in a research note on Friday, October 20th. Morgan Stanley decreased their price target on Celgene from $120.00 to $115.00 and set an underweight rating on the stock in a research note on Monday, October 23rd. SunTrust Banks decreased their price target on Celgene from $156.00 to $127.00 and set a buy rating on the stock in a research note on Friday, October 27th. Finally, William Blair reissued an outperform rating on shares of Celgene in a research note on Friday, October 20th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have given a buy rating to the stock. The stock presently has a consensus rating of Buy and an average price target of $131.18.
Shares of Celgene (CELG) traded up $1.42 during trading hours on Monday, hitting $106.00. The stock had a trading volume of 8,748,823 shares, compared to its average volume of 6,330,000. The stock has a market cap of $83,460.00, a price-to-earnings ratio of 25.00, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene has a fifty-two week low of $94.55 and a fifty-two week high of $147.17.
Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene had a return on equity of 43.32% and a net margin of 30.06%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.58 EPS. sell-side analysts expect that Celgene will post 6.68 EPS for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Arcadia Investment Management Corp MI increased its holdings in Celgene by 118.7% in the 3rd quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares in the last quarter. Thompson Davis & CO. Inc. boosted its position in Celgene by 5.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 43 shares during the last quarter. Robecosam AG purchased a new position in Celgene in the 3rd quarter valued at about $114,000. Capital Bank & Trust Co boosted its position in Celgene by 166.8% in the 3rd quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 517 shares during the last quarter. Finally, Guidant Wealth Advisors purchased a new position in Celgene in the 3rd quarter valued at about $119,000. Hedge funds and other institutional investors own 79.74% of the company’s stock.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with Analyst Ratings Network's FREE daily email newsletter.